REGN
Regeneron Pharmaceuticals, Inc.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2025
- #240
- Final score
- 59.63
- Years on list
- 6
↘ Down 124 since 2020
Compare · Up to four Russell 1000 companies
Put them side by side
Select two, three, or four Russell 1000 companies to compare their overall rank, year-by-year trajectory, and scores down to the category level.
- REGN· Regeneron Pharmaceuticals, Inc.
- QGEN· nan
- OGN· Organon & Co.
Figure 01 · Side-by-side summary
The headline numbers
QGEN
nanPharmaceuticals, Biotechnology & Life Sciences
- Rank · 2025
- #238
- Final score
- 59.67
- Years on list
- 6
↗ Climbed 247 since 2020
OGN
Organon & Co.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2025
- #269
- Final score
- 58.63
- Years on list
- 4
↗ Climbed 656 since 2022
Figure 02 · Rank trajectory
Where each line is going
Lower is better. The y-axis is inverted so a rising line means an improving rank. Missing years mean the company didn't make the top 100 that year.
Figure 03 · Pillar profile · 2025
Where each one wins
Latest-year ESG pillar scores, 0–100. The shaded bar shows relative strength across the selected companies for each pillar.
| Pillar | REGN | QGEN | OGN |
|---|---|---|---|
| Climate Change | 72.3 | 77.6 | 68.2 |
| Employee Relations | 54.1 | 53.9 | 61.8 |
| Environment | 59.1 | 57.2 | 54.1 |
| Stakeholders & Society | 61.1 | 45.6 | 58.8 |
| Human Rights | 41.8 | 59.0 | 58.1 |
| Governance | 55.2 | 54.5 | 46.5 |
| Performance Rating | 73.0 | 64.4 | 41.4 |